Role of Factor Xa Inhibitors in Cancer-Associated Thrombosis: Any New Data?

Table 2

Injectable factor Xa inhibitors [17, 18].

	Fondaparinux		Idraparinux	Idrabiotaparinux
Target	Factor Xa		Factor Xa	Factor Xa
Route of administration	Subcutaneous		Subcutaneous	Subcutaneous
Prevention dose	2.5 mg		Not available	Not available
Dosing schedule	Daily		Weekly	Weekly
Therapeutic dose	Acute VTE in conjunction with VKA: (ASCO) + (NCCN); 50 kg: 5 mg once daily; 50–100 kg: 7.5 mg once daily; >100 kg: 10 mg once daily		2.5 mg	3.0 mg
Bioavailability (%)	100		100	100
Half-life (𝑡1/2)	17 hours		60 days	60 days
Elimination	Renal		Renal	Renal
Antidote	None		None	Avidin
Market status/FDA approval	FDA approved for prevention and treatment of venous thromboembolism		In clinical trials	In clinical trials
Contraindication	(i) Patients with active bleeding; (ii) Bacterial endocarditis; (iii) Thrombocytopenia associated with positive antiplatelet antibodies	(i) Patients with CrCl <30 mL/min; (ii) Neuraxial anesthesia; (iii) Weight < 50 kg (prophylactic doses)	Not available	Not available
Monitoring parameters	Monitor hemoglobin, platelets		Not available	Not available

VTE: venous thromboembolism; VKA: vitamin K antagonist; ASCO: American Society of Clinical Oncology; NCCN: National Comprehensive Cancer Network; FDA: US Food and Drug Administration; CrCl: creatinine clearance.